Global Long-Acting Injectable (LAI) Antipsychotic Market Growth (Status and Outlook) 2023-2029

Global Long-Acting Injectable (LAI) Antipsychotic Market Growth (Status and Outlook) 2023-2029

The global Long-Acting Injectable (LAI) Antipsychotic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Long-Acting Injectable (LAI) Antipsychotic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Long-Acting Injectable (LAI) Antipsychotic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Long-Acting Injectable (LAI) Antipsychotic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Long-Acting Injectable (LAI) Antipsychotic players cover Alkermes, Eli Lilly and Company, Janssen Global Services, LLC, Abilify Maintena, Haldol, Otsuka Pharmaceutical, Aristada and Prolixin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.

LPI (LP Information)' newest research report, the “Long-Acting Injectable (LAI) Antipsychotic Industry Forecast” looks at past sales and reviews total world Long-Acting Injectable (LAI) Antipsychotic sales in 2022, providing a comprehensive analysis by region and market sector of projected Long-Acting Injectable (LAI) Antipsychotic sales for 2023 through 2029. With Long-Acting Injectable (LAI) Antipsychotic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-Acting Injectable (LAI) Antipsychotic industry.

This Insight Report provides a comprehensive analysis of the global Long-Acting Injectable (LAI) Antipsychotic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-Acting Injectable (LAI) Antipsychotic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-Acting Injectable (LAI) Antipsychotic market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-Acting Injectable (LAI) Antipsychotic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-Acting Injectable (LAI) Antipsychotic.

This report presents a comprehensive overview, market shares, and growth opportunities of Long-Acting Injectable (LAI) Antipsychotic market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Aripiprazole
Fluphenazine
Haloperidol
Others

Segmentation by application
Hospital
Retail Pharmacy
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alkermes
Eli Lilly and Company
Janssen Global Services, LLC
Abilify Maintena
Haldol
Otsuka Pharmaceutical
Aristada
Prolixin

Please note: the online download version of this report is for a global site license.